← all works
Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
The three-model screen
all 1,000 screened works →All three models called this out of scope.
stratum: aff_core · design weight: 5595.24 (the sample is stratified; any rate computed without the weight is wrong)
Claude Opus 4.8OUT
genre: empirical
about Canada: no
confidence: high
Conference poster reporting first results of a phase II AML treatment study; a clinical trial report.
GPT-5.6 (high)OUT
genre: empirical
about Canada: no
confidence: high
It reports a leukemia treatment study rather than studying research practice.
Grok 4.5OUT
genre: other
about Canada: no
confidence: high
AML clinical trial poster of a drug study; domain oncology trial, not research-on-research.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- Clinical Lymphoma Myeloma & Leukemia
- Topic
- Acute Myeloid Leukemia Research
- Field
- Medicine
- Canadian institutions
- Princess Margaret Cancer CentreUniversity of British ColumbiaMcGill UniversityUniversity of TorontoJewish General Hospital
- Funders
- —
- Keywords
- VenetoclaxAzacitidineMyeloid leukemiaMedicineInternal medicineMyeloidOncologyLeukemiaBiologyGenetics
- Has abstract in OpenAlex
- no